stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Gross margin
NewAmsterdam Pharma Company N.V.'s gross margin over the twelve months to 30 September 2026 was 100.0%, down 0.0 percentage points from fiscal 2025 (100.0%). Over the past ten years it has ranged from 0.00% (fiscal 2021) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 0.00 |
| FY2024 | 100.0% | 0.00 |
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.07 |
| FY2022 | 99.9% | 99.93 |
| FY2021 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 100.0% | 0.00 |
| Jun 2026 | 100.0% | 0.00 |
| Mar 2026 | 100.0% | 0.00 |
| Dec 2025 | 100.0% | 0.00 |
| 11 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| XNCR Xencor, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. | 100.0% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 29.2% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement